The deal, announced last Monday, values ImClone
at $70 per share, a premium of 51% to ImClone
's closing price on July 30, the day before Bristol made an offer of $60 a share for the 83% of the company it does not already own.
Our proposed acquisition of ImClone
represents an evolutionary development in our companies' seven-year-long relationship and is in the best interests of Bristol-Myers and ImClone
shareholders and employees and the patients we serve together," says chairman and chief executive officer James Cornelius.
In May 2004, Repligen and MIT filed an action in the United States District Court for the District of Massachusetts against ImClone
for infringement of United States Patent 4,663,281 based on ImClone
's manufacture and sale of Erbitux.
The assignments for ImClone
consisted of a 12,000-s/f interior renovation of the Company's finance department facility.
Under terms of the agreement, UCB and ImClone
Systems will share equally all agreed upon development costs for CDP-791 as well as worldwide profits derived from its commercialization in indications jointly pursued by the parties.
All Stewart knew when she ordered the sale of her 3,928 ImClone
shares was that, according to her broker; the price of the company's stock had dropped from $64 at opening to $58 under heavy selling (7.
As the legal noose tightens around Stewart, prosecutors are trying to determine what really happened in late December of last year, when, as she claims, a standing order to sell her ImClone
holdings was triggered when the stock price dropped to a predetermined level.
patents gives ImClone
and Abbott, a strong proprietary position for RCR technology worldwide," stated Samuel D.
will conduct preclinical studies utilizing the ETBs to evaluate their therapeutic potential in oncology.
with full general contracting services including carpentry, concrete and masonry, painting, wall covering and EIFS, as well as new carpeting and tile.
Board of Directors ImClone
Systems Incorporated 180 Varick Street New York, NY 10014 Care of Mr.
Icahn has said an unnamed third party has offered to acquire ImClone
for $70 a share, subject to an in-depth analysis, or due diligence.